

CVD Coding in Primary Care

Wednesday 24th July 2024 13:00 – 14:00

Agenda: NWL Innovations: BP case-finding

Agenda Item	Speaker	Time
Welcome & Housekeeping	Cat Caldwell, Imperial College Health Partners	5 mins
CVD Coding in Primary Care - Context	Dr Kuldhir Johal , NWL ICS Clinical Lead for Cardiovascular and Renal Disease (Interim)	5 mins
UCLP Searches	Joanne Peh - Hounslow	8 mins
Hypertension case finding – community pharmacy	Dr Mohsin Choudry and Luke Whitelaw - Ealing	8 mins
Cardiovascular Renal Metabolic	Dr Perviz Asaria - Harrow	8 mins
Business as Usual – Searches and Templates	Dr Kuldhir Johal	10 mins
Q&A	Moderated by ICHP	10 mins
Feedback and Close	Cat Caldwell, Innovation Manager, Imperial College Health Partners	5 mins

Housekeeping:



- Please remain on mute and with camera off unless speaking
- Questions? Enter into the chat, or, during our Q&A section at 13:45 use 'raise hand' function Please note we will be recording this meeting

Updates from previous meeting – CKD guidelines launched and Expressions of interest invited for MyHealth London




The new digital platform has officially launched and is already supporting people living with or at risk of CVD with self management.

- Over 80,000 page views so far and the potential to reach up to 170,000 NWL patients.
- Aims to replicate for CVD what Know Diabetes delivers for diabetes (20% reduction in primary care consultations & improved patient outcomes).
- Gives patients access to curated info, structured education and tools for implementing lifestyle changes, including culturally-tailored meal plans and exercise support.

Currently **40 practices** on board across NWL and we're now inviting more practices to sign up to give patients access to their personalised health dashboard. Fill in in this **EOI form here**, or contact **i.reddington1@nhs.net** – you will then be invited to sign up to the DCC (Data Controller Console).



Look at BP trend over time and also eg DM





Hypertension Dashboard

For more detailed analysis click on the bottom right corner of each quadrant



Prescribed dashboard:

Lifestyle


Population	
Total Patients	2,848,638
Number of Hypertensive Patients	317,113
Hypertension Prevelance %	11.1%
Number of Hypertensive Patients that also he Diabetes Ischaemic Heart Disease Heart Failure Coded CKD Atrial Fibrillation	103,780 36,064 13,181 44,562 20,610
Peripheral Arterial Disease	7,361
Stroke TIA	520 1,939
Map Population Overview dashboard:	Population Co-Morbidities, Complications & Risks dashboard:

Clinical	V.
Hypertensive Patients with BP Check in last 12m	263,505
Hypertensive Patients with BP below 150/90	277,942
Number of Hypertensive Admissions to Secondary Care	2,095
HTN Patients on Multiple Anti-Hypertensive Drug Classes in t	he last 12 months
No HTN Drugs prescribed	148,770
1 HTN Drug Class prescribed	14,875
2 HTN Drug Classes prescribed	138,058
3 HTN Drug Classes prescribed	10,754
4 HTN Drug Classes prescribed	3,962
> 4 HTN Drug Classes prescribed	694
Clinical Overview	Clinical Medication

46.7% of patients are	e on no medication – ensure the
are being given the	lifestyle advice and optimise the
b	lood pressure
Targ	et 120/80 or less
Whilst prevalence	on WSIC indicates 11.1% for all
ages when adjuste	d for over 18s – it is now 13.4%

months	不
16,044	
118,923	
114,377	
42,697	
92,710	
11,782	
	16,044 118,923 114,377 42,697 92,710

dashboard:





UCLP Proactive Framework: Hypertension

Hounslow

CVD Champion and Head of Hounslow PCN Pharmacy Services



Objectives of the UCLP framework series are:

- 1. Identify patients whose care needs optimising
- 2. Optimise care in clinical priority order, starting with those at highest risk
- 3. Standardise delivery of holistic proactive care by primary care teams including ARRS roles
- 4. Support GPs to safely manage workflow and release capacity
 - a. Stratify and prioritise
 - b. Task shift to the wider team

Hypertension: stratification and management



ARRS^{\$} roles/ other appropriately trained staff Gather information e.g. Up to date bloods, BP, weight, smoking status, run QRISK* score

Self management e.g. Education (blood pressure, CVD risk), self care (e.g. BP measurement), sign post self care

resources

Behaviour change e.g. Brief interventions and signposting e.g. smoking, weight, diet, exercise, alcohol

Stratification & Prioritisation Priority One

BP >180/120mmHg*** | 2a. BP >160/100mmHg***

Priority Two

2b. BP >140/90mmHg*** if BAME <u>AND</u> CV risk factors or co-morbidities**

2c. No BP reading in last 18 months

Priority Three

3a. BP >140/90mmHg***
if BAME <u>OR</u> CV risk factors
or comorbidities**

3b. BP >140/90mmHg*** or >150/90mmHg*** if > 80 years

Priority Four

4a. BP <140/90mmHg*** under age 80 years

4b. BP <150/90mmHg*** aged > 80 years

Prescribing Clinician

Optimise anti-hypertensive therapy and CVD risk reduction

- 1. Review: blood results, risk scores & symptoms
- 2. Check adherence and adverse effects
- Review complications and co-morbidities
- Initiate or optimise blood pressure medication
- CVD risk optimise lipid management and other risk factors

^{*}QRISK 3 score is recommended to assess CV risk for patients with Severe Mental Illness, Rheumatoid Arthritis, Systemic Lupus Erythematosus, those taking antipsychotics or oral steroids; SARRS = Additional Role Reimbursement Scheme

UCLP HTN - Hounslow

- Workforce PCN Pharmacists and Pharmacy Technicians
 - Upskilling on BP reviews
- BP@Home
- 23/24 Hounslow PCN Outcomes adopted the UCLP Proactive Care Frameworks risk stratification criteria:
 - Reduce the number of patients in Priority 1-3 to less than 10-20% of the hypertension register patients by 31st March 2024

Hounslow 23/24 CVD Strategy

- PCN senior pharmacists leads for BP
- BP Priorities:
 - UCLP framework for BP priorities 1&2
 - Undiagnosed SBP >160mmHg
 - UCLP framework for BP Hounslow indicator
 - BP QoF

Hounslow 23/24 BP Results

PCN	Indi	unslow PCN icator 10-20%)		P target ages)	NWL BP B&BB target (all ages)
	Apr23	Mar24	Sept23	Mar24	
Brentworth	37.7%	25.6%			2/6 (1 unknown)
Chiswick	29.8%	22.2%			3/8
Feltham&Bedfont	34.2%	25.4%			0/13
GreatWestRd	37.3%	24.8%			3/8
HounslowHealth	33.4%	22.8%			3/10

SBP>160mmgHg

Diagnosed&Undiagnosed – unchanged





Core20PLUS5 Ealing Hypertension Project Dr Mohsin Choudry Luke Whitelaw

July 2024



Hypertension Prevalence & Community Pharmacy BP Check Scheme

Measure			2020)-21		2021-22			2021-22		2022-23			2023-24			
		Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4
Prevalance		12.4%	12.6%	12.8%	13%	12.8%	12.8%	12.9%	13.1%	14%	14%	13%	14%	13%	13%	13%	14%
Total BP Che	ecks							2382		1685	2361	6585	7447	9148	8314	4390	1366
Total Referre	ed patients							331		244	267	842	1088	1114	721	395	104
Hypertension Prevalence & Pharmacy BP Checks – Ealing																	
	■Ealing P	revaland								NHSE F			3				
••••	· Baseline	19-20								Total BP	Check	ks in co	mmuni	ity phar	macies	6	
18.0% 16.0% 14.0% 12.0% 10.0% 8.0% 6.0% 4.0% 2.0%	-Total Re	ferred p	atients -	pharma	acy onwa	ard refe	erral										10,000 9,000 8,000 7,000 6,000 5,000 4,000 3,000 2,000 1,000
0.0%		Q2 (2020-2		4 Q		Q3)21-22		Q1		2 Q3 022-23	Q ²	4 Q		2 C		Q4	0



Artificial Intelligence: Hypertension Detection


Background and Methodology

- This analysis focusses on detection and helps to identify the gap (missing people with hypertension) based on estimates of undiagnosed prevalence.
- Using an Artificial Intelligence algorithm that set a high probability (60%) for those who are more at risk of developing hypertension. This method is statistically powerful, up-to-date and based on detailed demographics and geographical level (GP practices).
- Building on initial work in Harrow, this analysis aims to better understand North West London's residents at risk of undetected hypertension by key demographics (sex, age, ethnicity) and small geographical level (PCNs and GP practices).
- This will help inform focussed preventative interventions or commissioning plans to reduce inequalities and potentially prevent cardio vascular diseases.



Al Methodology

Our methodology built on FOCUS-ON with an addition of 'Manage & Coordinate' and identified 4 critical success factors to address pain points in current model



Al/Machine Learning Methodology

ML model was built to identify those at high risk of undiagnosed hypertension with a focus on eliminating data bias to address health inequality



Generate model

Gather information on patients and population statistics

Combine data from

WSIC & census

Machine learning tools detect underlying characteristics and patterns in HT patients

Model assigns risk score between 0 and 1 to each being diagnosed with hypertension





Comorbidities &

Demographic

(e.g., age, ethnicity, sex,

education, LSOA)



Care interaction (e.g., pharmacy interaction, in-home care)

patient indicating risk of





= 0.27



Included data features:

- Sociodemographic
- Census
- NHS facility in LSOA

Excluded due to data availability (% missing data past 12 months):

- Alcohol (91%)
- Cholesterol (79%)
- BMI (79%)
- Smoking (85%)

Removed bias features:


- Contact with health system
- Comorbidities
- Prescriptions


ID those at high risk for undiagnosed HT

Stratify patients based on predicted risk of diagnosis with hypertension


Create target cohorts

Cohorts created to capture individuals not included in original data






Target population grouped into specific cohorts across ethnicity, age, geography,




Hypertension – Ealing - Gender







Hypertension – Ealing - Age



Hypertension – Ealing - Ethnicity



Hypertension – Ealing - PCN



The Man Van – SCE and TEN PCN's HEALTH PARTNERS



	31st July - 29 S	•
	2023	
Scheduled	875	
Total Attended	765	
DNAs	110	14%
Ethnicities:		% of attendees
Black/Black British	64	8%
Asian/Asian British	78	10%
White	538	70%
Mixed/Other/Did not disclose	85	11%
age		% of attendees
>60	402	53%
50-59	295	39%
45-49	68	9%



67

ı	8%				
; }	10% 70%	Testing	1 07	% of attendees	
5	11%	Urinalysis	27 664	4% 87%	
	% of attendees	hba1c Primary care referrals:] 345 I	45% % of attendees	
2	53%	Hypertension	183	24%	
5	39%	Smoking	36	5%	
3	9%	Diabetes	38	5%	
		Secondary care referrals:	1		

Rapid access prostate

NV/hv

Oncogenetics

Rapid access haematuria

Then ManVan saw 765 Men aged over 45 and 24% (183 men) had suspected hypertension and were referred to GP for further testing and diagnosis.

% of attendees

9%	(of PSA tests)
----	----------------

1%

Next Steps - SystmOne Searches

Search One testing:

- Patients age >18 years and over
- On First line Hypertension treatment medication: ACE inhibitors, Angiotensin Receptor blockers or Calcium channel blockers
- Prescribed in the last 3 months.
 This is on all issues which can be acute or repeat.
- Without a read code for Hypertension (38341003), Heart failure (84114007), Ischaemic heart disease (414545008)

Results

Practice name	Number of patients returned in search OR number of patients selected to verify	Potential undiagnosed hypertensive in the results	Percentage of undiagnosed hypertensives
Practice A*	32	17	53%
Practice B	45	30	67%
Practice C	65	30	46%
Practice D	63	Difficult to tell but more than 50% might be hypertensive	



SystmOne Searches

Search two testing

 We are exploring a NWL wide search created on patients with a GP recorded high BP reading and no hypertension read code to see if following up these patients will result in a hypertension diagnosis






Cardio-renal-metabolic disease

Dr Perviz Asaria Consultant Cardiologist Harrow CVD Champion and CRM Hub Clinical Lead


Cardio-renal-metabolic disease

- · Common set of conditions bound by:
- Metabolically active (inflammatory) visceral adiposity
- The disease often improves with > 10% loss of body fat
- The disease often respond to drugs which mimic or promote this (SGLT2i and GLP-1RA)
- CKD both an intrinsic CRM condition
- But also aggravated by the presence of other
 CRM diseases






Weight trajectories






Evidence for effective intervention in CRM






When to intervene?





What is on EMIS already?





OHID rates

	Harrow QOF	London QOF	England QOF	Expected prevalence (Health survey)	Prevalence GAP for Harrow
CKD	3.4%	2.7%	4.2%	10%	7%
HTN	13.3%	10.9%	14.4%	25-30%	10-17%
DM	10.2%	6.9%	7.5%	14%	4%
NDH					
CVD	2.7%		3.0%		
BMI> 30	16.7%	20.9%	26.2%	23-26%	
Overweight (BMI >25)	52.8%	57.2%	64%	64%	





CVD Coding in Primary Care

Dr Kuldhir Johal

NWL ICS Clinical Lead for Cardiovascular and Renal Disease

(Interim)

Case identification on just BP reading alone and making it BAU – business as usual (NWL ICB Folder)

Name	Population Count	96	Last Run	Search Type	Scheduled	Code System
Hypertension - any BP reading systolic >120	4188	59%	17-Jul-2024	Patient	-40111111111111111111111111111111111111	SHOMED CT
P 8P systolic > 120 and on QOF register	1061	25%	17-Jul-2024	Patient		N/A
Hypertension 8P > 120 Systolic and hypertension monitoring coded	469	1196	17-Jul-2024	Patient		SNONED CT
BAU **Hypertension BP >120/80, hypertension monitoring and	640	94%	17-Jul-2024	Patient		N/A
Hypertension BP Systolic >120 and not on BP Systolic >140 Search list.	1947	44%	17-Jul-2024	Patient		N/A
Hypertension - any BP reading systolic >120 (2)	4188	59%	17-Jul-2024	Patient		SNONED CT
Hypertension BP >120 Systolic and hypertension monitoring coded	469	1196	17-Jul-2024	Patient		SNOMED CT
BAU **Hypertension BP >120/80, hypertension monitoring and	29	696	17-Jul-2024	Patient		N/A
and on BP medication	8	28%	17-Jul-2024	Patient		N/A
P Hypertension - any BP reading systolic >140	2341	33%	17-Jul-2024	Patient		SNOMED CT
P BP Systolic >140 on more than 3 occasions	1520	65%	17-Jul-2024	Patient		SNOMED CT
**BAU and on QOF register - Excluded list needs to be consid	961	63%	17-Jul-2024	Patient		N/A
P BP Systolic > 140 and has a hypertension monitoring code	120	5%	17-Jul-2024	Patient		SNOMED CT
BAU **BP Systolic >140, monitoring check done code and QOF	119	99%	17-Jul-2024	Patient		N/A
P BP Systolic > 140 and on QOF Hypertension register	1036	44%	17-Jul-2024	Patient		N/A
Systolic BP > 140 on more than 3 occasions	924	89%	17-Jul-2024	Patient		SNOMED CT
P Hypertension - any BP >140 and not on >160 search list	1247	53%	17-Jul-2024	Patient		N/A

> 140/90

Name	Population Count	56	Last Run	Search Type	Scheduled	Code System
P BP Systolic >140 on more than 3 occasions	1520	65%	17-Jul-2024	Patient	tiles series	SNOWED CT
**BAU and on QOF register - Excluded list needs to be consid	961	63%	17-Jul-2024	Patient		N/A
BP Systolic > 140 and has a hypertension monitoring code	120	5%	17-Jul-2024	Patient		SNOMED CT
P BAU **BP Systolic >140, monitoring check done code and QDF	119	99%	17-34-2024	Patient		NA
P BP Systolic > 140 and on QOF Hypertension register	1036	44%	17-Jul-2024	Patient		N/A
Systolic BP > 140 on more than 3 occasions	924	89%	17-Jul-2024	Patient.		SNOWED CT
Hypertension - any BP >140 and not on >160 search list	1247	53%	17-Jul-2024	Patient		N/A
Hypertension - any BP reading systolic >140 on more than 3 occasions	1334	57%	17-Jul-2024	Patient		SNOMED CT
Hypertension - any BP reading systolic >150 to 159	1386	20%	17-Jul-2024	Patient		SNOWED CT
BP systolic >150 to 159 and has a hypertension monitoring check d	96	7%	17-Jul-2024	Patient		SNOMED CT
BAU **BP systolic >150 to 159 hypertension monitoring code an	95	99%	17-Jul-2024	Patient		N/A
P BP Systolic >150 to 159 and on QOF register	891	64%	17-34-2024	Patient		NA
Hypertension - any BP Systolic >150 to 159 on 3 or more occasions	471	34%	17-Jul-2024	Patient		SNOMED CT
BP Systolic >150 to 159 on 3 or more occasions and hypertensio	39	8%	17-Jul-2024	Patient		SNOMED CT
**BAU BP Systolic >3 on 3 or more occasions, hypertension	39	100%	17-Jul-2024	Patient		N/A
Hypertension - any BP Systolic >150 to 159 on 3 or more occasi	400	85%	17-Jul-2024	Patient		N/A
₽ ** BALLAS above and on ODE register	400	100%	17-14-2024	Patient		MA


Getting started look at over BP >160/90

Name	Papulation Count	16	Last Run	Search Type	Scheduled .	Code System
P Hypertension - any 8P reading systolic >150 to 159	1386	20%	17-34-2024	Patient.		SNONED CT
P BP systolic >150 to 159 and has a hypertension monitoring check d	96	7%	17-34-2024	-3uf-2024 Patient		SNOMED CT
BAU **BP systolc >150 to 159 hypertension monitoring code an	95	99%	17-36-2024	Patient.		N/A
P BP Systolic >150 to 159 and on QOF register	891	64%	17-36-2024	Patient.		N/A
P Hypertension - any 8P Systolic >150 to 159 on 3 or more occasions	471	34%	17-34-2024	Patient		SHONED CT
P BP Systolic >150 to 159 on 3 or more occasions and hypertensio	39	8%	17-34-2024	Patient		SWOMED CT
→ "BAU BP Systolic >3 on 3 or more occasions, hypertension	39	100%	17-3:6-2024	Patient.		N/A
P Hypertension - any BP Systolic >150 to 159 on 3 or more occasi	sertension - any BP Systolic >150 to 159 on 3 or more occasi 400 85% 17-3ui-2024 Patient		N/A.			
*** BAU As above and on QOF register	400	100%	17-30-2024	Patient		R/A
P Hypertension - any BP reading systolic >160	1094	15%	17-34-2024	Patient		SNOHED CT
P BP systolic >160 and has a hypertension monitoring check done code	63	8%	17-34-2024	Patient.		SNOHED CT
P BAU **BP systolic >160, hypertension monitoring code and on Q	83	100%	17-301-2024	Patient		N/A
P BP Systolic > 160 and on QOF register	633	76%	17-3.6-2024	Patient		N/A
P Hypertension - any BP Systolic >160 on 3 or more occasions	496	45%	17-3/6-2024	Patient		SNOMED CT
P BP Systolic >160 on 3 or more occasions and hypertension monit	42	8%	17-3/-2024	Patient		SWOMED CT
**BAU BP Systolic >3 on 3 or more occasions, hypertension	42	100%	17-30-2024	Patient.		N/A
P Hypertension - any BP Systolic >160 on 3 or more occasions and	416	84%	17-34-2024	Patient		N/A
** BAU As above and on QOF register	416	100%	17-34-2024	Patient.		N/A
Patients with ne 8P reading	2251	32%	17-36-2024	Patient.		SWOMED CT
P and aged 40 to 99	124	6%	17-3/6-2024	Patient		N/A
P and aged over 60	19	1%	17-34-2024	Patient		N/A

Res Resources Infc Information Hillingdon Hillingdon Enterprise S&R > NW London ICB > Medicines Management v1 > Medicines Enhanced Service 24/25 > TGT2.4 Optimising Antihypertensive Management *Understands importance of blood pressure monitoring and control AND select one of the following: **Current treatment status **Current treatment status No previous entry **Current treatment status **Current treatment status **Current treatment status No previous entry **Current treatment status **Current treatment status **Current treatment status **Current treatment status **Current treatment status	NW	NWL ICS Hypertension Manager	ment ES 2024/25	
Life Lifestyle Inv. Investigations Mer Medicines Optimisation ES Res Resources Infc Information Millingdon Hillingdon Hillingdon Enterprise S&R > NW London ICB > Medicines Management v1 > Medicines Enhanced Service 24/25 > TGT2.4 Optimising Antihypertensive Management Management Millingdon Hillingdon Hillingdon Enterprise S&R > NW London ICB > Medicines Management v1 > Medicines Enhanced Service 24/25 > TGT2.4 Optimising Antihypertensive Management Management Mo previous entry Text NICE: NG136 Visual summary, Hypertension in adults: diagnosis and treatment		Pages «	Medicines Optimisation Enhanced Service - Optimising Antihypertensive Management	
Inv Investigations Met Medicines Optimisation ES Res Resources Info Information NW London Enterprise S&R > Medicines Team Brent Searches (Brent viewable) > Medicines Enhanced Service 24/25 > TGT2.4 Optimising Antihypertensive Management NW London Enterprise S&R > Harrow Reports > Medicines Management v1 > Medicines Enhanced Service 24/25 > TGT2.4 Optimising Antihypertensive Management Management Hillingdon Hillingdon Hillingdon Hillingdon Hillingdon Hillingdon Finderstands importance of blood pressure monitoring and control AND select one of the following: **Current treatment status No previous entry NICE: NG136 Visual summary. Hypertension in adults: diagnosis and treatment	Diag	Diagnosis		
Inv Investigations Medicines Optimisation ES Res Resources Info Information Medicines Optimisation ES Management Medicines Optimisation ES NW London Enterprise S&R > Harrow Reports > Medicines Management v1 > Medicines Enhanced Service 24/25 > TGT2.4 Optimising Antihypertensive Management Hillingdon Hillingdon Enterprise S&R > NW London ICB > Medicines Management v1 > Medicines Enhanced Service 24/25 > TGT2.4 Optimising Antihypertensive Management No previous entry AND select one of the following: *Current treatment status NICE: NG136 Visual summary, Hypertension in adults: diagnosis and treatment	Life	Lifestyle		
NW London Enterprise S&R > Harrow Reports > Medicines Management v1 > Medicines Enhanced Service 24/25 > TGT2.4 Optimising Antihypertensive Management Information Hillingdon Hillingdon Enterprise S&R > NW London ICB > Medicines Management v1 > Medicines Enhanced Service 24/25 > TGT2.4 Optimising Antihypertensive Management "Understands importance of blood pressure monitoring and control AND select one of the following: *Current treatment status Text No previous entry No previous entry No previous entry	Inve	Investigations		
Res Resources Management Hillingdon Hillingdon Enterprise S&R > NW London ICB > Medicines Management v1 > Medicines Enhanced Service 24/25 > TGT2.4 Optimising Antihypertensive Management "Understands importance of blood pressure monitoring and control AND select one of the following: "Current treatment status "Text NICE: NG136 Visual summary. Hypertension in adults: diagnosis and treatment	Med	Medicines Optimisation ES		n2
Hillingdon Enterprise S&R > NW London ICB > Medicines Management v1 > Medicines Enhanced Service 24/25 > TGT2.4 Optimising Antihypertensive Management *Understands importance of blood pressure monitoring and control AND select one of the following: *Current treatment status *Current treatment status No previous entry *Text No previous entry *No previous entry *Indian in adults: diagnosis and treatment in adults: diagnosis and treatment	Res	Resources		oked
Pressure monitoring and control AND select one of the following: *Current treatment status *Text NICE: NG136 Visual summary. Hypertension in adults: diagnosis and treatment	Info	Information	Hillingdon Enterprise S&R > NW London ICB > Medicines Management v1 > Medicines Enhanced Service 24/25 > TGT2.4 Optimising Antihypertensive	
*Current treatment status Text NICE: NG136 Visual summary. Hypertension in adults: diagnosis and treatment			*Understands importance of blood pressure monitoring and control *Text No previous entry	
Text NICE: NG136 Visual summary. Hypertension in adults: diagnosis and treatment			AND select one of the following:	
NICE: NG136 Visual summary. Hypertension in adults: diagnosis and treatment			*Current treatment status No previous entry	
			Text	
NICE: NG136 Patient decision aid on how do I control my blood pressure? Lifestyle options and choice of			A LANCE OF MAINTAINED AND THE RESIDENCE OF THE RESIDENCE OF THE STATE	
medicines			NICE: NG136 Patient decision aid on how do I control my blood pressure? Lifestyle options and choice of medicines	



Use as a motivation tool – heart age – print it off – age 62 but heart age 77



Summary

- Make every contact count, enter codes from patients/community pharmacies – since 28th June – being sent to local practices (GP Connect/email)
- Normal BP is less than 120/80
- Identify and optimise the care target is 120/80 or less
- Use "heart age" qrisk also action >20% and >10% and in CKD
- Look at trend over time, other co-morbidities eg diabetes/pre-diabetes
- Ensure all patients are given lifestyle advice
- At present nearly 47% of "hypertensives" are on no medication in NWL





Q&A

To get involved in ICHP's CVD education series



Give us feedback on what topics you think we should cover in this format by answering our survey.

For further information and/or to get involved with the ICHP CVD education series please contact:




<u>chanelle.corena@imperialcollegehealthpartners.com</u> or <u>catherine.caldwell@imperialcollegehealthpartners.com</u>

Resources

Please <u>click here</u> or visit <u>imperialcollegehealthpartners.com</u> /resource/cardiovascular_disease/ where we have collated clinical and patient resources for staff to access across NWL

We have also linked the ICB Cardiology webpage, where future resources will be updated.













... Next Time – September 2024

- WSIC
- CVDPrevent CVDPREVENT data available to March 2024

- Lipid Management
- Severe Hypertension
- Atrial Fibrillation

